Efficacy and safety of Capecitabine combined with Pyrrotinib in treatment of advanced breast cancer patients with HER-2 positive
Objective To study the efficacy and safety of Capecitabine combined with Pyrrotinib in the treatment of advanced breast cancer patients with HER-2 positive.Methods A total of 60 patients with HER-2 positive advanced breast cancer were selected from the re-lated department of our hospital from June 2021 to October 2022 for the study.According to the principle of random allocation,the 60 patients were divided into the experimental group and the control group randomly,30 cases in each group.The experimental group was treated with capecitabine tablets combined with pyrrotinib maleate tablets,and the control group was given capecitabine tablets combined with lapatinib tolu-ene sulfonate.Treatment was performed every 21 days until the disease progressed or the related toxic reactions could not be tolerated.The clin-ical efficacy,DCR,PFS and the occurrence of adverse reactions were compared between the two groups.Results After 2 cycles of treatment,the DCR of the experimental group was higher than that of the control group,with statistically significant differences(P＜0.05).The 6-month PFS,12-month PFS and median PFS in the experimental group were longer than those in the control group(P＜0.05).There was no signifi-cant difference in the incidence of treatment-related adverse events between the two groups(P＞0.05).Conclusion Pyrrotinib combined with capecitabine in the treatment of advanced breast cancer with positive HER-2 can improve DCR and prolong PFS in patients,and the ap-plication is safe and reliable,which is worthy of clinical promotion.
Breast cancerHuman Epidermal Growth Factor Receptor-2PyrrotinibCapecitabineLifetimeAdverse reactions
万方数据
维普
